(Q33843614)

English

Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

hypertriglyceridemia

1 reference

based on heuristic

inferred from title

author name string

Rader DJ

1

1 reference

Europe PubMed Central

29 July 2017

Rosas S

2

1 reference

Europe PubMed Central

29 July 2017

publication date

1 January 2000

1 reference

Europe PubMed Central

29 July 2017

Medical Clinics of North America

1 reference

Europe PubMed Central

29 July 2017

84

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

43-61

1 reference

Europe PubMed Central

29 July 2017

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cholesterol levels long-term after liver transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Pathogenesis of hyperlipidemia in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The compositional abnormalities of lipoproteins in diabetic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Diagnosis and classification of dyslipidemia in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid abnormalities in progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hypertriglyceridemia. A metabolic consequence of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) levels in end-stage renal failure and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Impact of serum lipids on long-term graft and patient survival after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Epidemiology of triglycerides: a view from Framingham

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) levels and heart transplantation atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Parathyroid hormone and hyperlipemia of uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid parameters including Lp(a) in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in liver transplant recipients: prevalence and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Familial hyper-alpha-lipoproteinemia: Studies in eighteen kindreds

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

High-density lipoprotein--the clinical implications of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Decreased clearance of low-density lipoprotein in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

A potential basis for the thrombotic risks associated with lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid abnormalities in end stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The Nephrotic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The role of apolipoprotein E genetic variants in lipoprotein disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apo(a) isoforms predict risk for coronary heart disease. A study in six populations

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid-lowering therapy and long-term survival in heart transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Plasma high density lipoproteins. Metabolism and relationship to atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in childhood nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid and lipoprotein (a) concentrations in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Plasma triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0025-7125(05)70206-6

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33843614&oldid=1971938692"